Experience

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant Pharmaceuticals…

Davis Polk advised the representatives of the several underwriters in connection with Iterum Therapeutics plc’s initial public offering of 6,150,000 ordinary shares, at $13.00 per…

Davis Polk advised the representatives of the underwriters in connection with the SEC-registered offering of 24,640,000 shares of common stock of Melinta Therapeutics, Inc., including…

Davis Polk advised the joint book-running managers for a $50 million public offering of common stock by Ardelyx, Inc. The common stock is listed on the NASDAQ Global Market under the…

Davis Polk advised the joint book-running managers in connection with the $86.25 million public offering of common stock of Coherus BioSciences, Inc. Based in Redwood City, California,…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 4,057,500 shares of common stock of Calyxt, Inc., including 457,500…

Davis Polk, together with Slaughter and May, is advising Shire plc in connection with a recommended cash and stock offer for Shire’s entire share capital by Takeda Pharmaceutical Company…

Davis Polk advised the joint book-running managers and representatives of the underwriters in the approximately $42.2 million initial public offering by ASLAN Pharmaceuticals Limited…

Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 5,000,000 shares of common stock of Unity Biotechnology, Inc. Unity…

Davis Polk advised the joint global coordinators in the Hong Kong initial public offering of Ping An Healthcare and Technology Company Limited. The gross proceeds from the offering…